Sugar-Coated Nanoparticles Shrink Glioblastoma Tumors in Mice

A research team at Oregon State University reported that mannose-coated cholesterol nanoparticles loaded with messenger RNA (mRNA) encoding the tumor-suppressor protein PTEN dramatically reduced glioblastoma burden in a mouse model. The work, published in the *Journal of Controlled Release* (Goo et al., 2026), demonstrated that the sugar “disguise” enables the particles to cross the blood-brain barrier (BBB) and deliver their genetic cargo directly to tumor cells.

ScienceAlert

Mannose, a glucose analogue, is recognized by the GLUT1 transporter that normally shuttles sugars into the brain. By densely attaching mannose to the nanoparticle surface, the researchers created a high-affinity ligand that outcompetes circulating glucose for GLUT1, facilitating BBB penetration. Once across, the particles accumulate preferentially in glioblastoma tissue, which overexpresses GLUT1, allowing localized PTEN expression that restores growth control in cancer cells.

ScienceAlert

In untreated mice, tumors occupied an average of 52 % of brain volume after 28 days. Treated mice showed a mean tumor burden of only 2.3 %. Median survival extended from 33 days (control) to 49 days with the sugar-coated formulation. Repeated dosing produced tumor shrinkage without any measurable toxicity in major organs.

ScienceAlert

The authors emphasize that the platform could be adapted for other neurological disorders requiring precise drug delivery across the BBB. They note that the approach solves two challenges simultaneously: efficient barrier crossing and selective tumor targeting. The team cautions that results are limited to murine models and that translation to human glioblastoma will require further validation in human cells and clinical trials.

ScienceAlert

• “Blood contains relatively high concentrations of glucose, and that's what the nanoparticles are competing against for GLUT1's attention,” — Oleh Taratula, pharmaceutical scientist

ScienceAlert

• “Glioblastoma is metabolically reprogrammed and expresses GLUT1 at three times the levels of normal brain tissue, so the particles preferentially accumulate in tumor tissue after crossing the blood-brain barrier,” — Olena Taratula, drug delivery scientist

ScienceAlert